Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1984 1
1985 1
1995 1
2000 2
2001 1
2003 2
2004 4
2005 3
2006 8
2007 4
2008 9
2009 5
2010 6
2011 3
2012 7
2013 7
2014 9
2015 7
2016 12
2017 20
2018 25
2019 24
2020 73
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 23349970

215 results
Results by year
Filters applied: . Clear all
Page 1
Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.
Hernán Pérez de la Ossa D, Lorente M, Gil-Alegre ME, Torres S, García-Taboada E, Aberturas Mdel R, Molpeceres J, Velasco G, Torres-Suárez AI. Hernán Pérez de la Ossa D, et al. PLoS One. 2013;8(1):e54795. doi: 10.1371/journal.pone.0054795. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349970 Free PMC article.
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, Dávila D, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez-Gómez P, Lorente M, Velasco G. López-Valero I, et al. Biochem Pharmacol. 2018 Nov;157:266-274. doi: 10.1016/j.bcp.2018.09.007. Epub 2018 Sep 7. Biochem Pharmacol. 2018. PMID: 30195736 Free article.
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
López-Valero I, Torres S, Salazar-Roa M, García-Taboada E, Hernández-Tiedra S, Guzmán M, Sepúlveda JM, Velasco G, Lorente M. López-Valero I, et al. Biochem Pharmacol. 2018 Nov;157:275-284. doi: 10.1016/j.bcp.2018.08.023. Epub 2018 Aug 18. Biochem Pharmacol. 2018. PMID: 30125556
Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy.
Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME, Aberturas MR, Molpeceres J, Di Marzo V, Torres Suárez AI. Hernán Pérez de la Ossa D, et al. J Control Release. 2012 Aug 10;161(3):927-32. doi: 10.1016/j.jconrel.2012.05.003. Epub 2012 May 10. J Control Release. 2012. PMID: 22580111
Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.
Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, Rausch WD. Moldzio R, et al. Phytomedicine. 2012 Jun 15;19(8-9):819-24. doi: 10.1016/j.phymed.2012.04.002. Epub 2012 May 7. Phytomedicine. 2012. PMID: 22571976
A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
Russo E, Guy GW. Russo E, et al. Med Hypotheses. 2006;66(2):234-46. doi: 10.1016/j.mehy.2005.08.026. Epub 2005 Oct 4. Med Hypotheses. 2006. PMID: 16209908
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M, Velasco G. Torres S, et al. Mol Cancer Ther. 2011 Jan;10(1):90-103. doi: 10.1158/1535-7163.MCT-10-0688. Mol Cancer Ther. 2011. PMID: 21220494 Free article.
Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.
Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Kozela E, et al. J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12. J Biol Chem. 2010. PMID: 19910459 Free PMC article.
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. Guzmán M, et al. Br J Cancer. 2006 Jul 17;95(2):197-203. doi: 10.1038/sj.bjc.6603236. Epub 2006 Jun 27. Br J Cancer. 2006. PMID: 16804518 Free PMC article. Clinical Trial.
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ, Nurmikko TJ, Young CA. Rog DJ, et al. Clin Ther. 2007 Sep;29(9):2068-79. doi: 10.1016/j.clinthera.2007.09.013. Clin Ther. 2007. PMID: 18035205 Clinical Trial.
215 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback